VISCHER advises Anokion SA in Lausanne in its closing of a Series A financing round for CHF 33 million ($37.5 million). A group of leading life sciences venture capitalists, consisting of Novartis Venture Fund, Novo Ventures and Versant Ventures, co-led the financing with additional participation by private investors. The spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL) has developed a technology for retraining white blood cells to induce therapeutic immune tolerance. The VISCHER team is lead by Matthias Staehelin (Corporate) with Ruben Masar and Janusz Marty.